Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-intensity Allogeneic BMT for Hematologic Malignancies
NCT01135329Phase 2Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Aug 2010
- Primary completion
- May 2012
- Modality
- Orthosteric Ligands, RNA-Targeting Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of fludarabine, busulfan, cyclophosphamide, mycophenolate mofetil, tacrolimus in lymphoma, leukemia, myelodysplastic syndrome (MDS), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Aug 2010; status: terminated.
02
Drugs
fludarabinebusulfancyclophosphamidemycophenolate mofetiltacrolimus
03
Conditions
lymphomaleukemiamyelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01135329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01135329.